Signatur Biosciences vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Simple PCR-based cancer diagnostics running on standard lab equipment to democratize complex disease detection; $7M raised May 2025 from YC S22 competing with Grail and Exact Sciences for accessible liquid biopsy.
About
Signatur Biosciences is a London-based diagnostics company developing simple PCR-based tests that can detect complex diseases like breast cancer and other conditions using standard qPCR machines already present in most clinical laboratories — making sophisticated molecular diagnostics as accessible and operationally simple as a COVID-19 PCR test. Founded in 2022 and a Y Combinator S22 graduate, Signatur raised $7 million in May 2025 to scale its affordable, point-of-care compatible diagnostic solutions that address critical accessibility gaps in cancer diagnostics.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.